NDAORALTABLET
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ARIMIDEX (anastrozole) by ANI Pharmaceuticals is aromatase inhibitors [moa]. First approved in 1995.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Arimidex (anastrozole) is an oral aromatase inhibitor approved in 1995 for hormone receptor-positive breast cancer in postmenopausal women. It works by blocking aromatase, an enzyme that converts androgens to estrogen in peripheral tissues, thereby reducing circulating estrogen levels. The drug is indicated for adjuvant and metastatic breast cancer treatment.
$0.004BPart D
LOE ApproachingDeclining commercial stage with 30% competitive pressure signals team consolidation and focus on cost management rather than growth initiatives.
Mechanism of Action
Aromatase Inhibitors
Pharmacologic Class:
Aromatase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
Started Jan 2024
231 enrolled
Breast Cancer
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Started Feb 2023
152 enrolled
Breast Cancer
Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.
Started Dec 2022
80 enrolled
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Started Jan 2021
14 enrolled
Refractory Endometrial AdenocarcinomaRefractory Endometrial CarcinomaRefractory Endometrial Clear Cell Adenocarcinoma+4 more
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Started Jan 2021
1,370 enrolled
ER-Positive HER2-Negative Breast Cancer
Worked on ARIMIDEX at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.